Search
CMLVAX100
go.drugbank.com/drugs/DB05164ExperimentalIt is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
KBP-COVID-19
go.drugbank.com/drugs/DB15858InvestigationalThe KBP-201 COVID-19 Vaccine was developed by British American Tobacco’s (BAT) U.S. biotech subsidiary, Kentucky BioProcessing (KBP). … As of July 2020, KBP is conducting a Phase 1/2 clinical trial to evaluate the safety and immunogenicity of KBP-COVID-19 vaccine in healthy patients (NCT04473690).
XTL-6865
go.drugbank.com/drugs/DB06058InvestigationalIt is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.
Ginger
go.drugbank.com/drugs/DB10344ApprovedInvestigationalGinger allergenic extract is used in allergenic testing.
Mixtures: Toe Corrector CompositeTildrakizumab
go.drugbank.com/drugs/DB14004ApprovedInvestigationalThe Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Amolimogene bepiplasmid
go.drugbank.com/drugs/DB04904InvestigationalAmolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV).
Vercirnon
go.drugbank.com/drugs/DB15250InvestigationalVercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD.
Obinepitide
go.drugbank.com/drugs/DB05045ExperimentalThese hormones are known to play a role in the regulation of food intake and appetite in man as satiety signal from the GI-tract to the CNS. … Obinepitide is a synthetic analogue of two natural human hormones, PYY and Pancreatic Polypeptide, which normally are released during a meal.
Apadenoson
go.drugbank.com/drugs/DB05009InvestigationalIt is developed by Bristol-Myers Squibb and is in phase II of clinical trials.